News & Updates

Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).

First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.

Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.